Related Experiment Video
Updated: Apr 17, 2026
06:47
Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
Published on: September 20, 2011
38.6K
Preparation, characterization and optimization of glipizide controlled release nanoparticles.
J Emami1, M S Shetab Boushehri2, J Varshosaz1
1Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Research Center, Isfahan University of Medical Sciences and Health Services, Isfahan, I.R. Iran.
Research in Pharmaceutical Sciences
|February 7, 2015
Summary
Researchers developed glipizide controlled-release nanoparticles using alginate and chitosan. This novel formulation offers a superior therapeutic alternative for managing type-two diabetes by improving drug delivery and efficacy.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Glipizide, a sulfonylurea, requires controlled release due to rapid gastrointestinal absorption and short elimination half-life.
- Alginate-chitosan nanoparticles (ACNP) offer a promising platform for glipizide delivery due to their release-limiting and bioadhesive properties.
Purpose of the Study:
- To develop glipizide-loaded alginate-chitosan nanoparticles (GlACNP) using ionotropic controlled gelation.
- To characterize GlACNP for particle size, zeta potential, entrapment efficiency, loading percent, and mean release time.
- To evaluate nanoparticle morphology, drug-excipient compatibility, and drug release kinetics.
Main Methods:
- Ionotropic controlled gelation method for nanoparticle preparation.
- Characterization of particle size, zeta potential, entrapment efficiency, and loading percent.
- Analysis of nanoparticle morphology, drug-excipient compatibility, and in vitro drug release kinetics.
Main Results:
- The ionotropic controlled gelation method produced GlACNP with favorable particle size, high entrapment efficiency, and controlled release characteristics.
- Nanoparticle morphology and drug-excipient compatibility were assessed.
- Box-Behnken design enabled efficient optimization of particle and release characteristics.
Conclusions:
- Glipizide-loaded alginate-chitosan nanoparticles prepared via ionotropic controlled gelation serve as an effective controlled delivery system.
- This novel formulation demonstrates potential as a superior therapeutic alternative to existing glipizide delivery systems.
- Optimized GlACNP offer enhanced glipizide delivery for type-two diabetes management.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
314
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
314
01:06Oral Hypoglycemic Agents: Glinides
996
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
996
01:20Modified-Release Drug Delivery Systems: Influencing Factors
170
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
170
01:19Modified-Release Drug Delivery Systems: Overview
211
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
211
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
231
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
231
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
144
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
144